These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28504612)

  • 1. Changes in the albumin glycation site, plasma pentosidine and esRAGE concentrations before and after intensive diabetic treatment in patients with abnormally high glycated albumin levels.
    Miyamoto H; Kohzuma T; Ohnishi A
    Ann Clin Biochem; 2018 Jan; 55(1):84-91. PubMed ID: 28504612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.
    Yamamoto M; Yamaguchi T; Yamauchi M; Sugimoto T
    Diabetes Care; 2009 Dec; 32(12):2263-8. PubMed ID: 19752174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control.
    Neumann T; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Sämann A
    Osteoporos Int; 2014 May; 25(5):1527-33. PubMed ID: 24599273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of Endogenous Secretory Receptor for Advanced Glycation End Products to Pentosidine Predicts Fractures in Men.
    Tamaki J; Kouda K; Fujita Y; Iki M; Yura A; Miura M; Sato Y; Okamoto N; Kurumatani N
    J Clin Endocrinol Metab; 2018 Jan; 103(1):85-94. PubMed ID: 29040721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
    Kurt A; Andican G; Siva ZO; Andican A; Burcak G
    J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes.
    Di Pino A; Urbano F; Zagami RM; Filippello A; Di Mauro S; Piro S; Purrello F; Rabuazzo AM
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1701-9. PubMed ID: 26885882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
    Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
    Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men.
    Lamb LS; Alfonso H; Norman PE; Davis TME; Forbes J; Müench G; Irrgang F; Almeida OP; Golledge J; Hankey GJ; Flicker L; Yeap BB
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4224-4231. PubMed ID: 30137355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentosidine plasma levels and relation with metabolic control in diabetic patients.
    Lapolla A; Reitano R; Baccarin L; Sartore G; Plebani M; Fedele D
    Horm Metab Res; 2005 Apr; 37(4):252-6. PubMed ID: 15952087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.
    Henle T; Deppisch R; Beck W; Hergesell O; Hänsch GM; Ritz E
    Nephrol Dial Transplant; 1999 Aug; 14(8):1968-75. PubMed ID: 10462279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease.
    Yang ZK; Shen Y; Shen WF; Pu LJ; Meng H; Zhang RY; Zhang Q; Chen QJ; De Caterina R; Lu L
    Int J Cardiol; 2015 Oct; 197():241-7. PubMed ID: 26142969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study.
    Du R; Zhang RY; Lu L; Shen Y; Pu LJ; Zhu ZB; Zhang Q; Hu J; Yang ZK; Ding FH; Zhang JS; Shen WF
    Cardiovasc Diabetol; 2018 Nov; 17(1):149. PubMed ID: 30482197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats.
    Odetti P; Traverso N; Cosso L; Noberasco G; Pronzato MA; Marinari UM
    Diabetologia; 1996 Dec; 39(12):1440-7. PubMed ID: 8960824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis.
    Fagugli RM; Vanholder R; De Smet R; Selvi A; Antolini F; Lameire N; Floridi A; Buoncristiani U
    Int J Artif Organs; 2001 May; 24(5):256-62. PubMed ID: 11420874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
    Hricik DE; Wu YC; Schulak A; Friedlander MA
    Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum pentosidine as an indicator of Alzheimer's disease.
    Meli M; Perier C; Ferron C; Parssegny F; Denis C; Gonthier R; Laurent B; Reynaud E; Frey J; Chamson A
    J Alzheimers Dis; 2002 Apr; 4(2):93-6. PubMed ID: 12214132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
    Saito R; Araki S; Yamamoto Y; Kusuhara K
    J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.